Terms of Use
Bracco Diagnostics Inc. (“Bracco”) offers products and services to healthcare professionals. Its contrast imaging agents and medical devices for use by healthcare professionals are regulated by the Food and Drug Administration in the United States.
This Website has been developed as a service of Bracco. Like any other service, in spite of our best efforts the information in this Website may become out of date over time. Unless otherwise indicated, the information contained in this site is for medical professionals only. Nothing on this Website should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action.
Bracco accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this Website.
These materials are provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.
This U.S.-based Website may link you to other Websites on the Internet, including the Websites for Bracco affiliates in other countries. Bracco cannot take responsibility for information found on third party Websites outside its control. While Bracco attempts to provide links only to third-party Websites that comply with all applicable laws and regulations and Bracco’s standards, please understand that the content on these third-party Websites is subject to change without notice to Bracco. We therefore cannot be responsible for, and accept no liability for, any information or opinion contained in any third-party Website.
Any personally identifiable information in electronic communications to this Website is governed by this site’s Privacy Policy. The owners of this Website shall be free to use or copy all other information in any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purposes. Such purposes may include disclosure to third parties and/or developing, manufacturing and/or marketing goods or services.
The sender of any communications to this Website or otherwise to the owners of this site shall be responsible for the content and information contained therein, including its truthfulness and accuracy.
Copyright and Intellectual Property
Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Bracco or any third party.
Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Bracco copyright.
Trademarks and service marks owned by or licensed to Bracco are presented as italicized typefaces. Bracco claims no ownership in, nor any affiliation with, any third-party trademarks appearing in this Website. Such third-party trademarks are used only to identify the products and services of their respective owners, and no sponsorship or endorsement on the part of Bracco should be inferred from the use of these marks.
Should any viewer of a Bracco published document respond with information including feedback data such as questions, comments, suggestions, or the like regarding the content of any such Bracco material, such information shall be deemed to be non-confidential and we shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation.
We shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.
VUEWAYTM (gadopiclenol) solution for injection
Indications
VUEWAY injection is indicated in adults and children aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:
- the central nervous system (brain, spine and surrounding tissues),
- the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
IMPORTANT SAFETY INFORMATION
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
- The risk for NSF appears highest among patients with:
- Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), or
- Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended VUEWAY dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.
Contraindications
VUEWAY injection is contraindicated in patients with history of hypersensitivity reactions to VUEWAY.
Warnings
Risk of nephrogenic systemic fibrosis is increased in patients using GBCA agents that have impaired elimination of the drugs, with the highest risk in patients chronic, severe kidney disease as well as patients with acute kidney injury. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.
Hypersensitivity reactions, including serious hypersensitivity reactions, could occur during use or shortly following VUEWAY administration. Assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders, administer VUEWAY only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, and observe patients for signs and symptoms of hypersensitivity reactions after administration.
Gadolinium retention can be for months or years in several organs after administration. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (brain, skin, kidney, liver and spleen). Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible.
Acute kidney injury requiring dialysis has occurred with the use of GBCAs in patients with chronically reduced renal function. The risk of acute kidney injury may increase with increasing dose of the contrast agent.
Ensure catheter and venous patency before injecting as extravasation may occur, and cause tissue irritation.
VUEWAY may impair the visualization of lesions seen on non-contrast MRI. Therefore, caution should be exercised when Vueway MRI scans are interpreted without a companion non-contrast MRI scan.
The most common adverse reactions (incidence ≥ 0.5%) are injection site pain (0.7%), and headache (0.7%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information for VUEWAY, including BOXED WARNING on Nephrogenic Systemic Fibrosis.
Manufactured for Bracco Diagnostics Inc. by Liebel-Flarsheim Company LLC – Raleigh, NC, USA 27616.
VUEWAY is a trademark of Bracco Imaging S.p.A.
VUEWAY™ (gadopiclenol) solution for injection
IMPORTANT SAFETY INFORMATION
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
